PBRM1 and neoplasm: In summary, our findings revealed that patients with POL&PBRM1 co-mutations exhibited significantly higher TMB, higher immunotherapy response signature scores, and more active anti-tumor immunity, suggesting a potentially favorable response to immunotherapy in these patients.